FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a composite enterosorbent of a silicone polymer specified in a group containing methyl monosilane acid xerogel or methyl monosilane acid hydrogel, differing by the fact that contains at least one ingredient specified in a group: lactulose, inulin, lignin, fructooligosaccharide, alginic acid in the form of pharmaceutically acceptable salts, chitosan, pectin, gum resin, beta-glucan in the amount of 0.1 to 10 portions per 1 weight portion of monosilane acid hydrogel or xerogel.
EFFECT: invention provides creating an agent to provide normalising the intestinal microflora and relieving the manifesting intoxication.
3 cl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING SORBENT BASED ON METHYL SILICIC ACID HYDROGEL | 2014 |
|
RU2693695C2 |
| METHOD OF PREVENTING ACUTE RESPIRATORY VIRAL INFECTIONS IN PRE-SCHOOL CHILDREN | 2006 |
|
RU2351349C2 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2701514C2 |
| LYOPHILISATE OF IMMOBILIZED MULTICOMPONENT SYNBIOTIC AND METHOD OF ITS PREPARATION | 2023 |
|
RU2811096C1 |
| METHOD OF CONTROLLING EFFECTIVENESS OF CORRECTING INTESTINAL MICROBIOCENOSIS DISTURBANCES | 2009 |
|
RU2410031C1 |
| PHARMACEUTICAL PREPARATION FOR INTESTINE BIOCOENOSIS NORMALISATION | 2007 |
|
RU2351344C2 |
| METHOD OF TREATING INTESTINAL DYSBACTERIOSIS | 2009 |
|
RU2397773C1 |
| METHOD FOR TREATMENT OF PATIENTS WITH CHRONIC KIDNEY DISEASE C3-C5 AT DIALYSIS STAGE, EXCLUDING PYELONEPHRITIS, UROLITHIASIS | 2017 |
|
RU2646467C1 |
| BIOLOGICALLY ACTIVE ADDITIVE FOR METABOLIC CORRECTION OF INTESTINAL MICROFLORA | 2022 |
|
RU2788716C1 |
| METHOD FOR CORRECTION OF ENDOGENUOUS INTOXICATION AND PREVENTION OF UNDESIRABLE SIDE REACTIONS OF ANTITUBERCULOUS MEDICATIONS IN TUBERCULOSIS PATIENTS | 2007 |
|
RU2347573C1 |
